Proteomic Analysis of Dorsal Root Ganglia in a Mouse Model of Paclitaxel-Induced Neuropathic Pain

• Published in: bioRxiv
• Main Authors: Hanna, Rania, Graur, Alexandru, Sinclair, Patricia, Mckiver, Bryan D, Paula D Bos, M, Imad Damaj, M, Kabbani, Nadine
• Format: Journal Article
• Language: English
• Published: United States Cold Spring Harbor Laboratory 25.06.2024
• Subjects: neuropathy; cancer; preclinical model; chemotherapy; dorsal root ganglion
• ISSN: 2692-8205; 2692-8205
• DOI: 10.1101/2024.06.20.599888

Paclitaxel is a chemotherapy drug widely used for the treatment of various cancers based on its ability to potently stabilize cellular microtubules and block division in cancer cells. Paclitaxel-based treatment, however, accumulates in peripheral system sensory neurons and leads to a high incidence rate (over 60%) of chemotherapy induced peripheral neuropathy. Using an established preclinical model of paclitaxel-induced peripheral neuropathy (PIPN), we examined proteomic changes in dorsal root ganglia (DRG) of adult male mice that were treated with paclitaxel (8 mg/kg, at 4 injections every other day) relative to vehicle-treated mice. High throughput proteomics based on liquid chromatography electrospray ionization mass spectrometry identified 165 significantly altered proteins in lumbar DRG. Gene ontology enrichment and bioinformatic analysis revealed an effect of paclitaxel on pathways for mitochondrial regulation, axonal function, and inflammatory purinergic signaling as well as microtubule activity. These findings provide insight into molecular mechanisms that can contribute to PIPN in patients.